ClinicalTrials.gg
CompletedNCT04168385MERGEUpdated Dec 8, 2025Results posted

MRX-800: A Long-Term Safety Study of Maralixibat in the Treatment of Cholestatic Liver Disease in Subjects Who Previously Participated in a Maralixibat Study

A Phase 2 interventional study of Maralixibat in Cholestatic Liver Disease, sponsored by Mirum Pharmaceuticals, Inc.. Completed at 17 sites in 8 countries. Open to participants aged 12 Months and older. Per ClinicalTrials.gov, last updated 2025-12-08.

Sponsored by Mirum Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
52
Allocation
Not applicable
Ages
12 Months and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 22 studies in Bile Duct Diseases with a site in United States — 2 open to participants now, 4 under way, none of them phase 3. Bile Duct Diseases · United States.

Enrollment
6th of 12
52 · median 46
Started
2020
with 1 other
Phase 2
6 of 22
none open now
Registered
11th of 22
by date
Lead sponsor
7 of 22
Mirum Pharmaceuticals, Inc.

Among the 22 studies in Bile Duct Diseases with a site in United States, this one is the 6th largest by enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2020, is one of 6 in phase 2, and was the 11th registered.

Bile Duct Diseases

50 studies on the registry are indexed under Bile Duct Diseases; 13 are open to participants now.

Browse Bile Duct Diseases studies →

Open to participants now

2 of the 22 studies in Bile Duct Diseases with a site in United States are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 9 Bile Duct Diseases studies recruiting now, 2 set no upper age limit and none stop at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.

This study: 12 Months and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Bile Duct Diseases with a site in United States, or all of them as a file.
02

Study summary

Evaluate the long-term safety of maralixibat (MRX) in subjects with cholestatic liver disease including, but not limited to, Alagille Syndrome (ALGS), Progressive Familial Intrahepatic Cholestasis (PFIC) and Biliary Atresia.

Read the detailed description

This is a multicenter, open-label study of maralixibat in subjects diagnosed with cholestatic liver disease (including, but not limited to ALGS, PFIC or Biliary Atresia) who have previously participated in a maralixibat clinical study. All subjects received maralixibat in the previous studies and will continues to receive maralixibat in this study.

03

Conditions studied

  • Cholestatic Liver Disease

Keywords

  • PFIC
  • ALGS
  • Maralixibat
  • Bile Duct Diseases
  • Liver Diseases
  • Biliary Tract Diseases
  • Digestive System Diseases
  • Pediatric
04

Who can participate

Ages eligible
12 Months and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria Subjects will need to meet all criteria below to be considered eligible for the study.

  1. Provide and assent (as applicable) per the Institutional Review Board/Ethics Committee (IRB/EC).
  2. Previously participated in a maralixibat study and with approval of the Medical Monitor. Previous participation is defined as:

    • Having completed the EOT Visit, for subjects coming from the maralixibat Phase 2 studies.
    • Having completed the entire duration of the study (i.e., core and extension, if applicable), for subjects coming from the maralixibat Phase 3 studies.
  3. At least 1 year of age
  4. Males, and females of non-. Males and non-pregnant, non-lactating females of childbearing potential who are sexually active must agree to use acceptable during the study and 30 days following the last dose of the study medication. Females of childbearing potential must have a negative pregnancy test.
  5. Caregivers (and/or age appropriate subjects) must have access to email or phone for scheduled remote visits if applicable.
  6. Subject and caregiver willingness to comply with all study visits and requirements.

Exclusion Criteria

A subject will be excluded from the study if any of the following exclusion criteria are met:

  1. Experienced an AE or SAE related to maralixibat during the lead-in protocol that led to permanent discontinuation of the subject from maralixibat.
  2. Any conditions or abnormalities (including laboratory abnormalities) which, in the opinion of the Investigator or Medical Monitor may compromise the safety of the subject or interfere with the subject participating in or completing the study.
  3. History of non-adherence to medical regimens, unreliability, medical condition, mental instability or cognitive impairment that, in the opinion of the Investigator or Sponsor medical monitor, could compromise the validity of informed consent, compromise the safety of the subject, or lead to non-adherence with the study protocol or inability to conduct the study procedures.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    Maralixibat

    Participants will all receive Maralixibat oral solution

    Drug: Maralixibat

Interventions

  • Maralixibat chloride oral solution orally twice daily (up to 1200\* mcg/kg/day), and according to indication. \*equivalent to 1140 mcg/kg/day maralixibat

    Also known as: Formerly LUM001 and SHP625

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events

    TEAE = Treatment-emergent Adverse Event; AESI = Adverse Event of Special Interest..

    Time frame: From informed consent through approximately 4.5 years, including 30 days after last dose.

Secondary outcomes

  1. Long-Term Effect on Pruritus

    Change from Baseline in Pruritus Severity assessed using the Clinician Scratch Score (CSS), a 5-point scale where 0 indicates no evidence of scratching and 4 indicates cutaneous mutilation with bleeding, hemorrhage, and scarring.

    Time frame: From Baseline through Week 160, including Change from Baseline values.

  2. Long-Term Effect on Serum Bile Acid Levels

    Time frame: From Baseline through Week 160, including Change from Baseline values.

07

Results

Posted Dec 8, 2025

Participant flow

A total of 52 participants were enrolled at 17 sites across 8 countries (Australia, Belgium, Canada, France, Poland, Spain, United Kingdom and United States). Participants were previously on maralixibat for an average of 4 years before entering this study.

Participant flow — Overall Study
MilestoneMaralixibat: ALGSMaralixibat: PFIC
Started4012
Completed3310
Not completed72
Withdrew: Withdrawal by subject10
Withdrew: Adverse event21
Withdrew: Liver transplant31
Withdrew: Listed for liver transplant10

Outcome measures

PrimaryIncidence of Treatment-Emergent Adverse Events

TEAE = Treatment-emergent Adverse Event; AESI = Adverse Event of Special Interest..

Time frame:
From informed consent through approximately 4.5 years, including 30 days after last dose.
Reported as:
Count of participants · Participants
Incidence of Treatment-Emergent Adverse Events
ParticipantsMaralixibat: ALGSMaralixibat: PFIC
At least one TEAE3612
TEAE ≥ 394
Serious TEAE103
Serious Treatment-Related Adverse Event00
Serious Treatment-Related TEAE00
TEAE Leading to Discontinuation of Study Drug31
TEAE Leading to Death10
Treatment-emergent AESI01
SecondaryLong-Term Effect on Pruritus

Change from Baseline in Pruritus Severity assessed using the Clinician Scratch Score (CSS), a 5-point scale where 0 indicates no evidence of scratching and 4 indicates cutaneous mutilation with bleeding, hemorrhage, and scarring.

Time frame:
From Baseline through Week 160, including Change from Baseline values.
Reported as:
Mean · score on a scale
Long-Term Effect on Pruritus
score on a scaleMaralixibat: ALGSMaralixibat: PFIC
Long-Term Effect on Pruritus-0.4 ± 0.89-0.3 ± 1.12
SecondaryLong-Term Effect on Serum Bile Acid Levels
Time frame:
From Baseline through Week 160, including Change from Baseline values.
Reported as:
Mean · µmol/L
Long-Term Effect on Serum Bile Acid Levels
µmol/LMaralixibat: ALGSMaralixibat: PFICMaralixibat: Overall
Long-Term Effect on Serum Bile Acid Levels-15.948 ± 31.4239-82.647 ± 136.4354-59.994 ± 111.0334

Adverse events

Collected over The timeframe for reporting adverse events was from informed consent through approximately 4.5 years, including 30 days after last dose.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Maralixibat: ALGS1/40 (2.5%)10/40 (25%)36/40 (90%)
Maralixibat: PFIC0/12 (0%)3/12 (25%)12/12 (100%)
Most frequent serious events
Showing 10 of 25
Most frequent serious events
EventMaralixibat: ALGSMaralixibat: PFIC
Anal fissureGastrointestinal disorders0/401/12
DyspepsiaGastrointestinal disorders0/401/12
Condition aggravatedGeneral disorders0/401/12
Lung abscessInfections and infestations0/401/12
ArthritisMusculoskeletal and connective tissue disorders0/401/12
PruritusSkin and subcutaneous tissue disorders0/401/12
Alagille syndromeCongenital, familial and genetic disorders2/400/12
Arteriovenous malformationCongenital, familial and genetic disorders1/400/12
Coarctation of the aortaCongenital, familial and genetic disorders1/400/12
Abdominal massGastrointestinal disorders1/400/12
Most frequent other events
Showing 10 of 88
Most frequent other events
EventMaralixibat: ALGSMaralixibat: PFIC
Corona virus infectionInfections and infestations9/409/12
Upper respiratory tract infectionInfections and infestations4/405/12
DiarrhoeaGastrointestinal disorders3/404/12
NasopharyngitisInfections and infestations7/404/12
Abdominal painGastrointestinal disorders6/403/12
ToothacheGastrointestinal disorders2/403/12
Pain in extremityMusculoskeletal and connective tissue disorders4/403/12
RashSkin and subcutaneous tissue disorders1/403/12
PyrexiaGeneral disorders7/402/12
ConstipationGastrointestinal disorders2/402/12

Baseline characteristics

Age, Customized
Age, Customized(Participants)Maralixibat: ALGSMaralixibat: PFICTotal
Age Categorical — 5 to 8 years8412
Age Categorical — 9 to 12 years18725
Age Categorical — 13 to 18 years9110
Age Categorical — > 18 years505
Sex: Female, Male
Sex: Female, Male(Participants)Maralixibat: ALGSMaralixibat: PFICTotal
Female19726
Male21526
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Maralixibat: ALGSMaralixibat: PFICTotal
Hispanic or Latino516
Not Hispanic or Latino211132
Unknown or Not Reported14014
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Maralixibat: ALGSMaralixibat: PFICTotal
American Indian or Alaska Native000
Asian011
Native Hawaiian or Other Pacific Islander000
Black or African American303
White221032
More than one race011
Unknown or Not Reported15015
Region of Enrollment
Region of Enrollment(participants)Maralixibat: ALGSMaralixibat: PFICTotal
Canada202
Belgium202
United States18826
Poland112
United Kingdom8311
Australia404
France404
Spain101
08

Study locations

17 sites
  • Children'S Hospital Los Angeles
    Los Angeles, California 90027, United States
  • Riley Hospital For Children
    Indianapolis, Indiana 46202, United States
  • Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • Children Hospital of Pittsburgh
    Pittsburgh, Pennsylvania 15224, United States
  • Baylor College of Medicine/Texas Children's Hospital
    Houston, Texas 77030, United States
  • Seattle Children's Hospital
    Seattle, Washington 98105, United States
  • Children's Hospital Westmead
    Westmead, New South Wales 2145, Australia
  • The Royal Children'S Hospital Melbourne
    Parkville, Victoria 3052, Australia
  • Cliniques Universitaires Saint-Luc
    Brussels, Belgium
  • Hospital for Sick Children
    Toronto, Canada
  • Hopital Necker-Enfants Malades
    Paris, 75015, France
  • Hopital Kremlin Bicetre
    Paris, 94275, France
  • The Children's Memorial Health Institute
    Warsaw, 04-730, Poland
  • Hospital Universitario La Paz- Hospital Materno Infantil
    Madrid, 261, Spain
  • Birmingham Children's Hospital
    Birmingham, United Kingdom
  • Leeds Teaching Hospital NHS Trust
    Leeds, LS1 3EX, United Kingdom
  • Paediatric Liver Center, Kings College Hospital
    London, SE5 9RS, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2020 to primary completion in Sep 2024, 55 months.

Results were first posted in Dec 2025, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2019
First posted
Nov 19, 2019
StartActual
Jan 16, 2020
Primary completionActual
Sep 4, 2024
CompletionActual
Sep 4, 2024
Results first posted
Dec 8, 2025
Last update
Dec 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04168385
Responsible party
Sponsor
First posted
Nov 19, 2019
Start date
Jan 16, 2020
Primary completion
Sep 4, 2024
Completion
Sep 4, 2024
Results posted
Dec 8, 2025
Last update
Dec 8, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Maralixibat

Start the discussion